Von Eschenbach Likely To Put FDA Critical Path Initiative Back On Track
This article was originally published in The Tan Sheet
Executive Summary
The appointment of National Cancer Institute Director Andrew von Eschenbach to FDA acting commissioner is likely to revitalize the agency's stalled Critical Path initiative